- Kezar Life Sciences (NASDAQ:KZR) is up 6% in premarket on Orphan Drug status by the FDA for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM).
- PM is a type of muscle disease that leads to inflammation of muscles and their related tissues, like the blood vessels that supply them. It can cause muscle weakness and pain.
- DM is a long-term inflammatory disorder which affects skin and the muscles. Its symptoms are generally a skin rash and worsening muscle weakness over time.
- KZR-616 is a first-in-class selective immunoproteasome inhibitor.Currently, the company is enrolling patients in the Phase 2 PRESIDIO trial to evaluate KZR-616 for the treatment of PM and DM.
- https://seekingalpha.com/news/3625263-kezar-life-sciences-kzrminus-616-orphan-drug-in-u-s-for-autoimmune-inflammatory-disorders
Friday, October 23, 2020
Kezar Life Sciences' KZR-616 an Orphan Drug in U.S. for autoimmune inflammation
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.